Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue
The DOI matches its Crossref record.
Abstract
Little is known about the long-term results of treating gastric carcinoid tumors with a slow-release somatostatin analogue. We report three patients with type 1 and 2 gastric carcinoid tumors who were treated in the above mentioned way and followed for 27-50 months. In all cases, alternative endoscopic or surgical management was considered but deemed inappropriate. Treatment with a slow-release somatostatin analogue was begun in light of a favorable recent report. The result was regression or complete disappearance of macroscopic fundal tumors. No side-effects were reported and, most notably, none of the patients developed gallstones. This small study may help define the optimal duration, dose, and administration interval of the treatment. Slow-release somatostatin analogue is a safe and efficacious treatment for type 1 and 2 gastric carcinoid tumors, and can be used when tumors are growing rapidly. Slow-release somatostatin analogue represents an alternative to repeated endoscopic treatment or high-risk surgery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Ramage, J. K., Ahmed, A., Ardill, J., Bax, N., Breen, D. J., Caplin, M. E., Corrie, P., Davar, J., Davies, A. H., Lewington, V, et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300831 · Cited by 952
NANETS Treatment Guidelines: Well-Differentiated Neuroendocrine Tumors of the Stomach and Pancreas
Kulke, M. H., Anthony, L. B., Bushnell, D. L., de Herder, W. W., Goldsmith, S. J., Klimstra, D. S., Marx, S. J., Pasieka, J. L., Pommier, R. F., Yao, J. C., et al. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181ebb168 · Cited by 574
ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms
Delle Fave, G., Kwekkeboom, D. J., Van Cutsem, E., Rindi, G., Kos-Kudla, B., Knigge, U., Sasano, H., Tomassetti, P., Salazar, R., & Ruszniewski, P. (2012) · Neuroendocrinology · doi:10.1159/000335595 · Cited by 327
NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine Tumor
Vinik, A. I., Woltering, E. A., Warner, R. R. P., Caplin, M., O'Dorisio, T. M., Wiseman, G. A., Coppola, D., & Go, V. L. W. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181ebaffd · Cited by 287
Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate
Merola, E., Sbrozzi-Vanni, A., Panzuto, F., D’Ambra, G., Di Giulio, E., Pilozzi, E., Capurso, G., Lahner, E., Bordi, C., Annibale, B., et al. (2012) · Neuroendocrinology · doi:10.1159/000329043 · Cited by 132
Vannella, L., Sbrozzi-Vanni, A., Lahner, E., Bordi, C., Pilozzi, E., Corleto, V. D., Osborn, J. F., Delle Fave, G., & Annibale, B. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04659.x · Cited by 109
Metadata
- Authors
- Manfredi, S., Pagenault, M., de Lajarte-Thirouard, A.-S., & Bretagne, J.-F.
- Venue
- European Journal of Gastroenterology & Hepatology
- Published
- 2007-11
- Volume
- 19
- Issue
- 11
- Pages
- 1021-1025
- ISSN
- 0954-691X (ISSN-L)
- OpenAlex
- W1999860903
- Cited by
- 43
- References
- 0
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.